Under the agreement, McLaren will provide a capital investment to assist with upgrades at Karmanos facilities and to fund clinical trials and research programs. Though the cancer institute and the Karmanos Cancer Center, which provides clinical care to patients, will become part of McLaren, they will each retain their names and remain separate legal entities, according to the news release.
The McLaren Cancer Institute will be known as the Barbara Ann Karmanos Cancer Institute. McLaren’s cancer clinical trials program will be merged into the Karmanos Cancer Institute Clinical Trials Office.
“McLaren has worked hard to develop Michigan’s largest network of cancer centers and providers, and in looking for ways to strengthen cancer care across our communities, we looked to the leader — Karmanos,” Philip Incarnati, president and CEO of McLaren Health Care Corp., said in the release. “This new relationship will transform the way new cancer-fighting therapies and treatments reach more patients in communities across Michigan.”
The agreement will become effective in the next several weeks after both organizations’ boards review and amend their governing documents.
More Articles on Hospital-Physician Transactions:
TriHealth Acquires Pulmonary Physician Group Practice
5 Questions Hospitals Should Ask Before Acquiring a Physician Practice
Southcoast Health System is on Provider Recruiting Spree
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
